Kymera Therapeutics
IPO
Revolutionary Medicines Catalyzed by Protein Degradation
- Headquarters
- Boston, Massachusetts
- Employees
- 51–200
- Founded
- 2016
- Business Model
- Other
- Website
- kymeratx.com
- Total Funding
- $167.0M
- Last Round
- $102.0M Series CMar 2020
About
Kymera Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation to develop oral small molecule medicines addressing critical health problems in immunology and oncology. Its proprietary platform enables degradation of disease-causing proteins, transforming treatment paradigms for undruggable targets.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account